Skip to content
myglp1coverage.com

BCBS North Dakota · Osa

BCBS North Dakota coverage for Zepbound (Osa)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea

Qualification pathways

You can qualify through any one of these.

Moderate to severe OSA in adults with obesity

All of:

  • Adult patient (age >= 18)
  • Diagnosis of moderate to severe obstructive sleep apnea (OSA)
  • Obesity (BMI >= 30 kg/m2)

Documentation to bring

  • Documentation of moderate to severe OSA diagnosis
  • Documentation of obesity (BMI >= 30 kg/m2)

Not covered when

  • Coadministration with other tirzepatide-containing products is not recommended
  • Coadministration with any GLP-1 receptor agonist is not recommended

Policy note: FDA indication listed as moderate to severe OSA in adults with obesity. Specific AHI threshold, PAP trial requirement, and other OSA-specific PA criteria are not enumerated in the provided document text — only the FDA indication summary is presented. Document does not specify 'moderate to severe' in terms of AHI cutoff values.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea

Qualification pathways

You can qualify through any one of these.

Moderate to severe OSA in adults with obesity

All of:

  • Adult patient (age >= 18)
  • Diagnosis of moderate to severe obstructive sleep apnea (OSA)
  • Obesity (BMI >= 30 kg/m2)

Documentation to bring

  • Documentation of moderate to severe OSA diagnosis
  • Documentation of obesity (BMI >= 30 kg/m2)

Not covered when

  • Coadministration with other tirzepatide-containing products is not recommended
  • Coadministration with any GLP-1 receptor agonist is not recommended

Policy note: FDA indication listed as moderate to severe OSA in adults with obesity. Specific AHI threshold, PAP trial requirement, and other OSA-specific PA criteria are not enumerated in the provided document text — only the FDA indication summary is presented. Document does not specify 'moderate to severe' in terms of AHI cutoff values.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

All Zepbound policies under BCBS North Dakota · Check your card